

04-09-01

A

WDN/SAS:gte 04/06/01 44876.doc  
 Attorney Reference Number 4239-55414  
 PATENT

EXPRESS MAIL LABEL NO. EL754020489US  
 DATE OF DEPOSIT: April 6, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION  
 COMMISSIONER FOR PATENTS  
 WASHINGTON, D.C. 20231

Jc825 U.S. PTO  
 09/828000  
 04/06/01

Transmitted herewith for filing is the continuing patent application of:

Inventor(s): Giovanna Tosato, M.D. and Sandra E. Pike

For: VASOSTATIN AS MARROW PROTECTANT

Enclosed are:

- ☒ 48 pages of specification, 6 pages of claims, and an abstract
- ☒ 25 sheet(s) of drawings
- ☒ 3 pages of an Oath or Declaration (UNSIGNED)
  - ☐ Newly executed (original or copy)
  - ☐ A copy of oath or declaration filed with the prior application (37 C.F.R. § 1.63(d))
    - ☐ The inventors to be deleted are set forth on a separate sheet attached hereto
- ☐ Microfiche Computer Program (Appendix)
- ☒ Nucleotide and/or Amino Acid Sequence Submission
  - ☒ Computer Readable Copy
  - ☒ Paper Copy (identical to computer copy), 5 pages
  - ☒ Statement in compliance with 37 C.F.R. § 1.821 verifying identity of above copies
- ☐ An assignment of the invention to: \_\_\_\_\_, a Recordation Cover Sheet, and a Recordal fee of \$40.00
- ☐ Information Disclosure Statement.
- ☐ Form PTO-1449 and copies of documents listed thereon

Continuing Application:

- ☐ Continuation
- ☐ Divisional
- ☒ Continuation-in-part (CIP)

Information from Prior Application:

Prior Application Number: PCT/US99/23240  
 Examiner: N/A  
 Art Unit: N/A

WDN/SAS:gte 04/06/01 44876.uuc  
Attorney Reference Number 4239-55414  
PATENT

EXPRESS MAIL LABEL NO. EL754020489US  
DATE OF DEPOSIT: April 6, 2001

FILING FEE					
For	Claims Filed	Number allotted	Number Extra	Rate	Basic Fee
					\$710.00
Total Claims	49	20	= 29	\$18.00	\$ 522.00
Independent Claims	7	3	= 4	\$80.00	\$ 320.00
Multiple Dependent Claim Fee				\$270.00	\$0.00
TOTAL FILING FEE					\$1,552.00

- ☒ A check in the amount of \$1,552.00 to cover ☒ filing fee and ☐ assignment recordal fee is enclosed.
- ☒ Assignee for this application is or will be the Government of the United States of America, and applicants request that this information be listed on the published application.
- ☒ The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference herein.
- ☒ The Director is hereby authorized to charge any additional fees which may be required in connection with the filing of this application and recording any assignment filed herewith, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL  
LEIGH & WHINSTON, LLP

By William D. Noonan  
William D. Noonan, M.D.  
Registration No. 30,878

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446

cc: Docketing Secretary

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tosato et al.

Art Unit: To be assigned


Application No.: To be assigned

CERTIFICATE OF EXPRESS MAILING

Filed: Herewith

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on April 6, 2001 as Express Mail Label No. EL754020489US in an envelope addressed to: BOX PATENT APPLICATION, COMMISSIONER FOR PATENTS, WASHINGTON D.C. 20231.

For: VASOSTATIN AS MARROW  
PROTECTANT

  
William D. Noonan, M.D.  
Attorney for Applicant

Examiner: To be assigned

Date: April 6, 2001

STATEMENT IN COMPLIANCE WITH 37 C.F.R. § 1.821(f)


BOX PATENT APPLICATION  
COMMISSIONER FOR PATENTS  
Washington, DC 20231

Sir:

In compliance with 37 C.F.R. § 1.821(f), the undersigned declares that the nucleotide and/or amino acid sequences presented in the paper copy of the "Sequence Listing" submitted herewith are the same as the sequences contained in the computer-readable form of said "Sequence Listing." No new matter has been added.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL  
LEIGH & WHINSTON, LLP

By   
William D. Noonan, M.D.  
Registration No. 30,878

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 226-7391  
Facsimile: (503) 228-9446